Endole® offers a new treatment option which can reduce or eliminate the substantial burden of
endometriosis without causing the side effects which are normally involved in currently
available therapies. The market for the treatment of endometrios is huge with large untapped
patient populations. Endometriosis is underserved in terms of diagnosis and treatment and
hence the medical need for new treatment options is high. Datamonitor estimates that
endometriosis affects around 10% of women of reproductive age, equating to 17 million
sufferers across the seven major markets in 2009*. The patient potential is set to increase
further, driven by e.g. environmental factors, increased awareness and diagnosis. GlobalData
estimates that the global endometriosis market was valued at USD 1.7 billion in 2009 and is
forecast to grow at a CAGR of 4.3% to reach US 2.3 billion by 2016.

The cause of endometriosis is still unknown and current therapies include either surgery or
pharmacotherapy. However, surgical treatment of endometriosis is associated with high relapse
rates and currently available therapeutic drugs can only be used for short-term relief of
symptoms associated with endometriosis as safety concerns such as decreased bone mineral
density and side effects such as hot flushes limit its long-term use. In addition, therapeutic
drugs currently available do not allow women in reproductive age to become pregnant.

Endole, which is a completely hormone-free treatment, has in clinical studies
demonstrated effectiveness in reducing endometriosis related pain.

Isifera® Isifera In Vivo Fertilization is a new and unique solution for patients with infertility problems.
The treatment addresses a significant and growing market. Datamonitor estimates that in the
seven major markets there are more than 11.5 million women suffering from infertility, and
approximately 1.6 million women aged 20-45 are willing and able to receive infertility
treatment. In 2009, the infertility market was estimated at USD 4.2 billion and expected to
reach USD 4.6 billion by 2016.

The most effective therapy against infertility available today is in-vitro fertilization (IVF), with
a pregnancy rate around 30-35% per cycle and approximately 60% after three cycles. Isifera
fills a gap in the repertoire for physicians and infertile couples and hence, while waiting to
proceed to IVF or other treatments, Isifera provides an attractive option to consider. In
addition, Isifera can be positioned as the therapy step before and in connection with IVF and
FSH/Insemination as well as attract women avoiding heavy hormone treatments or couples
who cannot afford IVF treatment.

Isifera has in clinical studies showed high efficacy and was very well tolerated.

*The seven major markets include US, France, Germany, Italy, Spain, UK, and Japan